Table 5.
Top 15 co-targets for countering drug resistance under ETA treatment
| Co-target | Exp | Essential | Annotation | Ref |
|---|---|---|---|---|
| pgk | 0.12 | In Vitro essential | phosphoglycerate kinase | [55] |
| Rv3802c | 0.25 | In Vitro essential | conserved membrane protein | [55] |
| Rv1343c | 0.37 | Not Essential | lipoprotein | [65,66] |
| Rv1474c | 0.03 | Not Essential | transcriptional regulator | |
| Rv0481c | 0.08 | Not Essential | hypothetical protein | |
| Rv2455c | 0.63 | Not Essential | oxidoreductase alpha subunit | |
| accA2 | 0.36 | In Vitro essential | acetyl-/propionyl-CoA carboxylase alpha subunit | [59] |
| fadD18 | 0.05 | Not Essential | fatty-acid-CoA ligase | |
| fadA5 | 0.45 | Not Essential | acetyl-CoA acetyltransferase | [2] |
| atpB | 0.46 | In Vitro essential | ATP synthase A chain | [55,67] |
| Rv2367c | 0.28 | Not Essential | hypothetical protein | |
| Rv3355c | 0.01 | Not Essential | conserved hypothetical protein | |
| Rv2199c | 0.55 | Not Essential | conserved membrane protein | |
| Rv3310 | 1.38 | Not Essential | acid phosphatase | [68] |
| nadC | 0.59 | Not Essential | nicotinate-nucleotide pyrophosphatase | [69] |